Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Sierra Oncology Inc
(NQ:
SRRA
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Jun 30, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
-
Bid (Size)
54.96 (50)
Ask (Size)
55.00 (2)
Prev. Close
54.99
Today's Range
N/A - N/A
52wk Range
N/A - N/A
Shares Outstanding
24,419,349
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
The Daily Biotech Pulse: Addex Terminates Parkinson's Study, Expanded Use Of Rhythm's Obesity Drug, FDA Approval For AbbVie's Skyrizi In Crohn's Disease
June 17, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Sierra Oncology Announces Submission of New Drug Application for Momelotinib to US Food & Drug Administration
June 17, 2022
From
Sierra Oncology
Via
Business Wire
Performance
More News
Read More
6 Biotech Stocks to Buy Now Ahead of These June Catalysts
June 03, 2022
Via
InvestorPlace
3 Biotech Stocks to Buy Before They Boom
June 01, 2022
Via
InvestorPlace
Recap: Sierra Oncology Q1 Earnings
May 06, 2022
Via
Benzinga
Analyst Ratings for Sierra Oncology
April 14, 2022
Via
Benzinga
Momelotinib Pivotal Phase 3 Data Receives Oral Presentation at American Society of Clinical Oncology Annual Meeting
May 26, 2022
From
Sierra Oncology
Via
Business Wire
Sierra Oncology Announces Oral Presentation of Momelotinib Pivotal Phase 3 Data at European Hematology Association Annual Meeting
May 12, 2022
From
Sierra Oncology
Via
Business Wire
Sierra Oncology Reports First Quarter 2022 Results
May 06, 2022
From
Sierra Oncology
Via
Business Wire
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 05, 2022
From
Sierra Oncology
Via
Business Wire
SIERRA ONCOLOGY INVESTOR ALERT - Kuznicki Law PLLC Investigates Proposed Sale of Sierra Oncology, Inc - SRRA
May 02, 2022
From
Kuznicki Law PLLC
Via
Business Wire
SIERRA ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sierra Oncology, Inc - SRRA
April 25, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
The Week Ahead In Biotech (April 17-April 23): J&J, Abbott Earnings, Adcom Test For TG Therapeutics And More
April 17, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2022
April 14, 2022
Via
Benzinga
Analyzing Sierra Oncology Inc's Short Interest
April 14, 2022
Via
Benzinga
Advancements of CAR-T Cell Therapies Importance Grows While Cancer Cases Increasing
April 14, 2022
Via
FinancialNewsMedia
12 Health Care Stocks Moving In Wednesday's Intraday Session
April 13, 2022
Via
Benzinga
Why Is Creatd (CRTD) Stock Up Today?
April 13, 2022
Via
InvestorPlace
Dear KLDO Stock Fans, Mark Your Calendars for April 28
April 13, 2022
Via
InvestorPlace
Why Is Sierra Oncology (SRRA) Stock Up Today?
April 13, 2022
Via
InvestorPlace
Sierra Oncology Stock Is Soaring: Here's Why
April 13, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2022
April 13, 2022
Via
Benzinga
Biotech Stock Sierra Soars On GSK Buyout As Halozyme Nabs Antares
April 13, 2022
Via
Investor's Business Daily
The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More
April 13, 2022
Via
Benzinga
SRRA Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Sierra Oncology, Inc. Is Fair to Shareholders
April 13, 2022
From
Halper Sadeh LLP
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.